Chronic myelogenous leukemia: molecular monitoring in clinical practice
Use of tyrosine kinase inhibitor imatinib has led to significant progress in chronic myeloid leukemia (CML) treatment. To date, genetic monitoring is a mandatory attribute of therapy with tyrosine kinase inhibitors. The purpose of this study was to access the imatinib therapy efficacy in CML patient...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-07-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/39 |
| _version_ | 1797855519412584448 |
|---|---|
| author | N. R. Ryabchikova I. R. Minniakhmetov G. Sh. Safuanova D. V. Islamgulov A. S. Karunas E. E. Khusnutdinova |
| author_facet | N. R. Ryabchikova I. R. Minniakhmetov G. Sh. Safuanova D. V. Islamgulov A. S. Karunas E. E. Khusnutdinova |
| author_sort | N. R. Ryabchikova |
| collection | DOAJ |
| description | Use of tyrosine kinase inhibitor imatinib has led to significant progress in chronic myeloid leukemia (CML) treatment. To date, genetic monitoring is a mandatory attribute of therapy with tyrosine kinase inhibitors. The purpose of this study was to access the imatinib therapy efficacy in CML patients using complete molecular genetic monitoring by standard cytogenetics, realtime polymerase chain reaction and mutational analysis. Correlation between cytogenetic and molecular response was shown. Heterogeneity of molecular response in each patient group was revealed by expression of BCR-ABL. Kinase domain mutations were detected in 32 % of CML patients resistant to imatinib. |
| first_indexed | 2024-04-09T20:24:59Z |
| format | Article |
| id | doaj.art-173561f4690c416095548e3da683e58a |
| institution | Directory Open Access Journal |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| last_indexed | 2024-04-09T20:24:59Z |
| publishDate | 2014-07-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj.art-173561f4690c416095548e3da683e58a2023-03-30T20:15:10ZrusABV-pressОнкогематология1818-83462413-40232014-07-018171610.17650/1818-8346-2013-8-1-7-1654Chronic myelogenous leukemia: molecular monitoring in clinical practiceN. R. Ryabchikova0I. R. Minniakhmetov1G. Sh. Safuanova2D. V. Islamgulov3A. S. Karunas4E. E. Khusnutdinova5Bashkortostan State Medical University, Ministry of Health of RussiaInstitute of Biochemistry and Genetics, Ufa Scientific Center, Russian Academy of SciencesBashkortostan State Medical University, Ministry of Health of RussiaInstitute of Biochemistry and Genetics, Ufa Scientific Center, Russian Academy of SciencesInstitute of Biochemistry and Genetics, Ufa Scientific Center, Russian Academy of SciencesInstitute of Biochemistry and Genetics, Ufa Scientific Center, Russian Academy of SciencesUse of tyrosine kinase inhibitor imatinib has led to significant progress in chronic myeloid leukemia (CML) treatment. To date, genetic monitoring is a mandatory attribute of therapy with tyrosine kinase inhibitors. The purpose of this study was to access the imatinib therapy efficacy in CML patients using complete molecular genetic monitoring by standard cytogenetics, realtime polymerase chain reaction and mutational analysis. Correlation between cytogenetic and molecular response was shown. Heterogeneity of molecular response in each patient group was revealed by expression of BCR-ABL. Kinase domain mutations were detected in 32 % of CML patients resistant to imatinib.https://oncohematology.abvpress.ru/ongm/article/view/39chronic myeloid leukemiamolecular genetic monitoringph-positive cells mutations |
| spellingShingle | N. R. Ryabchikova I. R. Minniakhmetov G. Sh. Safuanova D. V. Islamgulov A. S. Karunas E. E. Khusnutdinova Chronic myelogenous leukemia: molecular monitoring in clinical practice Онкогематология chronic myeloid leukemia molecular genetic monitoring ph-positive cells mutations |
| title | Chronic myelogenous leukemia: molecular monitoring in clinical practice |
| title_full | Chronic myelogenous leukemia: molecular monitoring in clinical practice |
| title_fullStr | Chronic myelogenous leukemia: molecular monitoring in clinical practice |
| title_full_unstemmed | Chronic myelogenous leukemia: molecular monitoring in clinical practice |
| title_short | Chronic myelogenous leukemia: molecular monitoring in clinical practice |
| title_sort | chronic myelogenous leukemia molecular monitoring in clinical practice |
| topic | chronic myeloid leukemia molecular genetic monitoring ph-positive cells mutations |
| url | https://oncohematology.abvpress.ru/ongm/article/view/39 |
| work_keys_str_mv | AT nrryabchikova chronicmyelogenousleukemiamolecularmonitoringinclinicalpractice AT irminniakhmetov chronicmyelogenousleukemiamolecularmonitoringinclinicalpractice AT gshsafuanova chronicmyelogenousleukemiamolecularmonitoringinclinicalpractice AT dvislamgulov chronicmyelogenousleukemiamolecularmonitoringinclinicalpractice AT askarunas chronicmyelogenousleukemiamolecularmonitoringinclinicalpractice AT eekhusnutdinova chronicmyelogenousleukemiamolecularmonitoringinclinicalpractice |